Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial

BACKGROUND: Fosmanogepix is a first-in-class antifungal targeting the fungal enzyme Gwt1, with broad-spectrum activity against yeasts and moulds, including multidrug-resistant fungi, formulated for intravenous (IV) and oral administration. METHODS: This global, multicenter, non-comparative study eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Pappas, Peter G, Vazquez, Jose A, Oren, Ilana, Rahav, Galia, Aoun, Mickael, Bulpa, Pierre, Ben-Ami, Ronen, Ferrer, Ricard, Mccarty, Todd, Thompson, George R, Schlamm, Haran, Bien, Paul A, Barbat, Sara H, Wedel, Pamela, Oborska, Iwona, Tawadrous, Margaret, Hodges, Michael R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545531/
https://www.ncbi.nlm.nih.gov/pubmed/37596890
http://dx.doi.org/10.1093/jac/dkad256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545531/
https://www.ncbi.nlm.nih.gov/pubmed/37596890
http://dx.doi.org/10.1093/jac/dkad256

Ejemplares similares